This study sought to test 2 hypotheses : 1 ) fibroblast growth factor ( FGF ) -23 identifies patients with stable ischemic heart disease ( SIHD ) at high risk of cardiovascular events independent of clinical factors , renal function , and established cardiovascular biomarkers ; and 2 ) FGF-23 identifies patients who derive greater clinical benefit from angiotensin-converting enzyme inhibitor therapy .